Home › Trials › NCT05772559

Molecular profiling and drug testing for pediatric acute myeloid leukemia

Acute Myeloid Leukemia At Initial Diagnosis and/or Relapse in Children, Teenagers and Young Adults: Molecular Profiling, Multidrug Testing and MSC Interaction Studies - ALARM3

Observational Assistance Publique - Hôpitaux de Paris · NCT05772559

This study is trying to learn more about pediatric acute myeloid leukemia by looking at patients' cells to find out why some treatments don’t work and to test new drug options for kids and young adults with this cancer.

Quick facts

Study typeObservational
Enrollment500 (estimated)
AgesN/A to 25 Years
SexAll
SponsorAssistance Publique - Hôpitaux de Paris Academic / other
Locations28 sites (Amiens and 27 other locations)
Trial IDNCT05772559 on ClinicalTrials.gov

What this trial studies

This study focuses on understanding pediatric acute myeloid leukemia (AML) by collecting biological samples from patients at initial diagnosis and during relapse. It aims to evaluate the genomic profiling of leukemic cells to identify genetic factors associated with treatment resistance and relapse risk. Additionally, the study will investigate the interaction of bone marrow mesenchymal stem cells and conduct ex vivo drug testing to explore potential therapeutic options. The research is observational and involves patients aged 0-25 years with various forms of AML.

Who should consider this trial

Good fit: Ideal candidates include individuals aged 0-25 years with newly diagnosed or relapsed acute myeloid leukemia, or those with a genetic predisposition to the disease.

Not a fit: Patients with chronic myeloid leukemia or those who refuse to participate may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to improved treatment strategies and better outcomes for children and young adults with acute myeloid leukemia.

How similar studies have performed: While this approach is focused on pediatric AML, similar studies in adult populations have shown promise in understanding genetic factors and improving treatment outcomes.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* 0-25 years old
* Newly diagnosed de novo or secondary Acute Myeloid Leukemia (AML) or
* Relapsed or refractory AML or
* Patients with genetic predisposition to develop AML or
* Patients without haematological malignancy nor AML genetic predisposition syndrome who undergo bone marrow aspirate as part of standard of care
* Signed informed consent of parents for patients aged less than 18 years old or signed informed consent of the patient for patients aged 18 and over.

Exclusion Criteria:

* Refuse to participate
* Chronic myeloid leukemia (CML)
* Lack of health insurance (French social security)
* Under protection (tutelle, curatelle or sauvegarde de justice)
* Pregnancy or breastfeeding

Where this trial is running

Amiens and 27 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Acute Myeloid LeukemiaGenetic Predisposition to Disease
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.